GSK’s Asthma Drug Wins FDA Approval

GlaxoSmithKline’s Nucala (Mepolizumab) therapy has been approved by the FDA to treat severe asthma attacks in combination with other drugs. Nucala is an injection administered once every four weeks that is approved as an add-on maintenance treatment for patients aged 12 and older.
 
In trials, patients who received Nucala had fewer asthma attacks that required hospitalization or emergency-room visits and reported longer breaks between asthma attacks.
 
The most common reported side effects included redness, swelling and itching in the injection area, back pain and fatigue.